Drug Type T-lymphocyte cell therapy |
Synonyms Autologous EBV specific Cytotoxic T cells (Tessa Therapeutics), MABEL CTLs (Tessa Therapeutics), TT-10X |
Mechanism EBNA1 modulators(Epstein-Barr nuclear antigen 1 modulators), Latent membrane protein 1 modulators, Protein BARF1 modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Nasopharyngeal Carcinoma | Phase 3 | US | 01 Jul 2014 | |
Advanced Nasopharyngeal Carcinoma | Phase 3 | MY | 01 Jul 2014 | |
Advanced Nasopharyngeal Carcinoma | Phase 3 | SG | 01 Jul 2014 | |
Advanced Nasopharyngeal Carcinoma | Phase 3 | TW | 01 Jul 2014 | |
Advanced Nasopharyngeal Carcinoma | Phase 3 | TH | 01 Jul 2014 | |
Nasopharyngeal Carcinoma | Phase 3 | US | 01 Jul 2014 | |
Nasopharyngeal Carcinoma | Phase 3 | MY | 01 Jul 2014 | |
Nasopharyngeal Carcinoma | Phase 3 | SG | 01 Jul 2014 | |
Nasopharyngeal Carcinoma | Phase 3 | TW | 01 Jul 2014 | |
Nasopharyngeal Carcinoma | Phase 3 | TH | 01 Jul 2014 |
Phase 3 | Nasopharyngeal Carcinoma First line | 330 | kxslmjqkfa(zmjiexiysj) = kxxrsalsov canactyvxs (vhjujacmmx ) | Negative | 01 Sep 2024 | ||
Gemcitabine+carboplatin | kxslmjqkfa(zmjiexiysj) = tuaxvjaclx canactyvxs (vhjujacmmx ) | ||||||
Phase 3 | 330 | carboplatin+gemcitabine (Chemo + EBV-CTL) | awyyfnitki(wtwzjiqcwo) = uanlzynlgy xxqihykgjj (legvmpokde, hcrojfpmaj - tfcgzlyegm) View more | - | 28 Jun 2023 | ||
carboplatin+gemcitabine (Chemo Only) | awyyfnitki(wtwzjiqcwo) = tuedgbxvgu xxqihykgjj (legvmpokde, utbcffcnns - byjdxyzupm) View more |